Akeso Inc. (9926.HK) ("Akeso", "the Company") released its 2024 annual report, emphasizing the company's key achievements in drug research, clinical development, and commercialization.
Sportschosun on MSN4h
KAIST research team develops world's first damaged vision recovery retina regeneration technologyWith 300 million patients with retinal disease worldwide, Korean researchers have succeeded in developing retina regeneration ...
We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback